BeiGene v. MSN Pharmaceuticals: Zanubrutinib Patent Dispute Dismissed Without Prejudice
BeiGene USA and BeiGene Switzerland filed a four-patent infringement action against MSN Pharmaceuticals and MSN Laboratories in New Jersey over generic zanubrutinib 80 mg capsules. After 256 days, all claims and counterclaims were dismissed without prejudice — with each party bearing its own costs.
Four-Patent Zanubrutinib Dispute Ends in Stipulated Dismissal
In March 2024, BeiGene USA, Inc. and BeiGene Switzerland GmbH filed suit in the U.S. District Court for the District of New Jersey against MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited, asserting infringement of four U.S. patents — US10927117B2, US11591340B2, US11851437B2, and US11786531B1 — all relating to zanubrutinib, the active ingredient in BeiGene’s BTK inhibitor Brukinsa. The trigger was MSN’s filing of an Abbreviated New Drug Application (ANDA) for generic zanubrutinib 80 mg capsules.
The case closed on November 19, 2024, via a Rule 41(a)(1) stipulated dismissal without prejudice. All of BeiGene’s infringement claims and MSN’s counterclaims and defenses were terminated simultaneously. Critically, no merits determination was made — no court found infringement or invalidity — and each party was ordered to bear its own legal costs, suggesting a negotiated resolution rather than a contested adjudication.
At 256 days, the case resolved faster than many Hatch-Waxman ANDA litigations, which typically run 18–30 months or longer. The without-prejudice dismissal preserves BeiGene’s ability to refile against MSN should circumstances change, such as a new ANDA submission or revised patent landscape. The terms of any underlying commercial arrangement — licensing, settlement, or consent agreement — are not disclosed in the public record.
Filing to Dismissed without Prejudice in 256 days
256 days from filing to closure — shorter than the average ANDA patent suit in D.N.J.
Dismissed without prejudice: what the stipulated exit means for both parties
Rule 41(a)(1) stipulated dismissal — no merits ruling
A Rule 41(a)(1) dismissal requires agreement from all parties and carries no adjudication on the merits. The court made no finding of infringement, validity, or enforceability regarding any of the four zanubrutinib patents. This mechanism is commonly used in Hatch-Waxman litigation when parties reach a private resolution or agree to pause proceedings, while preserving procedural rights.
No merits determinationBeiGene can refile — but the record is silent on why
A without-prejudice dismissal means BeiGene’s infringement claims are not extinguished — they may be reasserted in future proceedings. This contrasts with a with-prejudice dismissal, which bars refiling. The public record does not reveal whether the parties reached a licensing deal, consent judgment, or simply agreed to stand down. The distinction matters: a without-prejudice exit could signal ongoing negotiations or a strategic pause rather than a permanent resolution.
Refiling rights preservedMSN’s ANDA path remains legally unresolved
MSN Pharmaceuticals and MSN Laboratories exit this proceeding without a court finding of non-infringement or invalidity — meaning MSN cannot rely on this case as legal precedent for its ANDA product launch. Absent a confirmed license or consent agreement, MSN faces residual patent risk if it attempts to launch generic zanubrutinib 80 mg capsules before the asserted patents expire. The without-prejudice nature of the dismissal limits the defensive value of this outcome for MSN.
No clearance ruling for MSNGeneric zanubrutinib market entry timeline remains uncertain
Zanubrutinib (Brukinsa) is a high-value oncology asset in the BTK inhibitor class. With four patents asserted and no merits ruling, the IP barriers to generic entry remain formally intact. Other ANDA filers in the zanubrutinib space should monitor whether BeiGene pursues similar actions or whether MSN’s exit signals a broader licensing strategy. The each-party-bears-own-costs provision is consistent with negotiated exits but provides no signal on commercial terms.
Generic entry timeline unclearFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | BEIGENE USA, INC. | Company | Oncology biopharmaceutical group — holder of US10927117B2 and 3 related zanubrutinib patentsSearch in Eureka ↗ |
| Co-Plaintiff | BEIGENE SWITZERLAND GMBH | Company | Search in Eureka ↗ |
| Defendant | Msn Pharmaceuticals, Inc. | Company | Generic pharmaceutical manufacturer seeking ANDA approval for zanubrutinib 80 mg capsulesSearch in Eureka ↗ |
| Co-Defendant | MSN Laboratories Private Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Katelyn O’Reilly | Attorney | Counsel for BEIGENE USA, INC.Search in Eureka ↗ |
| Plaintiff counsel | Lauren Ruth Malakoff | Attorney | Counsel for BEIGENE USA, INC.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for BEIGENE USA, INC.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’Reilly Falanga LLP | Law Firm | Representing BEIGENE USA, INC.Search in Eureka ↗ |
| Defendant counsel | Gregory D. Miller | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | MARCUS O. TUBIN | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Timothy P. Gonzalez | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Rivkin Radler LLP | Law Firm | Representing Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal is framed under Rule 41(a)(1), confirming both parties consented — no court order was required. The phrase ‘including all claims and defenses … and all counterclaims and defenses’ signals a complete bilateral exit: BeiGene’s infringement claims and MSN’s invalidity or non-infringement counterclaims are equally extinguished without prejudice. The each-party-bears-own-costs clause is notable; fee-shifting is absent, which is consistent with a negotiated departure rather than a contested win or loss for either side.
US10927117B2 and 3 further patents — zanubrutinib BTK inhibitor composition and formulation
The four asserted patents — US10927117B2, US11591340B2, US11851437B2, and US11786531B1 — cover zanubrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor developed by BeiGene and commercialised as Brukinsa. The patents span multiple application families, suggesting coverage across compound composition, pharmaceutical formulation, and potentially method-of-use claims. US10927117B2 is the earliest in the group, with the others issuing through 2022 and 2023, reflecting active continuation prosecution to extend IP protection as the product scaled commercially.
Zanubrutinib is a commercially significant oncology asset approved for multiple B-cell malignancies including mantle cell lymphoma and CLL/SLL. BeiGene’s multi-patent strategy creates overlapping layers of protection — a common approach in small-molecule oncology to deter generic entry and increase the cost and complexity of ANDA challenges. For competitors, the breadth of the patent family means that designing around a single patent may not be sufficient to clear the IP landscape; each of the four asserted patents represents a distinct potential barrier to generic zanubrutinib commercialisation.
Should your team run an FTO against BeiGene’s zanubrutinib patent family?
Any pharmaceutical company developing, manufacturing, or seeking ANDA approval for generic zanubrutinib — particularly 80 mg capsule formulations — should treat BeiGene’s four-patent portfolio as an active enforcement risk. The without-prejudice dismissal of this case means no court has cleared MSN’s product, and BeiGene retains full rights to refile. R&D teams evaluating BTK inhibitor generics or formulation modifications must assess claim scope across all four patents before committing to development investment.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US10927117B2, US11591340B2, US11851437B2, and US11786531B1 against your product specifications — identifying which claims present genuine blocking risk and which may be vulnerable to prior art. Eureka also tracks continuation filings and prosecution history, giving your team early warning if BeiGene extends its zanubrutinib IP coverage further.
Run a freedom-to-operate analysis on US10927117B2 to assess your product’s exposure
Run FTO in Eureka →Similar BTK inhibitor ANDA patent cases in U.S. District Courts
Explore comparable Hatch-Waxman ANDA infringement actions involving BTK inhibitor patents litigated in federal district courts, including the District of New Jersey.
What this case signals for the BTK inhibitor patent landscape
BeiGene’s rapid four-patent filing and fast exit raise key questions for generic challengers and brand-side IP teams in oncology.
Without-prejudice exits preserve enforcement options in ANDA litigation
BeiGene’s decision to dismiss without prejudice — rather than seek a consent judgment or litigate to trial — is consistent with a strategy that keeps IP leverage intact. Brand-side teams in high-value oncology spaces routinely use this mechanism to manage generic challengers while commercial negotiations proceed privately.
Four-patent assertions signal BeiGene’s defensive depth on zanubrutinib
Asserting four patents across multiple application families suggests a layered IP strategy around zanubrutinib’s composition, formulation, and use. Competitors and ANDA filers should assess whether each patent represents an independent barrier or whether validity challenges could narrow the blocking landscape.
BEIGENE v Msn — key questions answered
The case was dismissed without prejudice by stipulation of all parties under Rule 41(a)(1) on November 19, 2024. No merits determination was made — no court found infringement or invalidity of the four asserted zanubrutinib patents. Each party bears its own costs and attorneys’ fees.
BeiGene asserted four U.S. patents: US10927117B2, US11591340B2, US11851437B2, and US11786531B1. All relate to zanubrutinib — the active ingredient in Brukinsa — and were asserted in response to MSN’s ANDA filing for generic zanubrutinib 80 mg capsules.
Yes. A dismissal without prejudice does not extinguish BeiGene’s claims. BeiGene retains the right to refile infringement actions against MSN based on the same patents, for example if MSN proceeds toward commercial launch of generic zanubrutinib or files a revised ANDA. This contrasts with a with-prejudice dismissal, which would bar refiling.
The each-party-bears-own-costs provision means no fee-shifting occurred — neither side was awarded attorneys’ fees or litigation costs. In U.S. patent litigation this is the default position, but its inclusion in a stipulated dismissal is consistent with a negotiated exit rather than a contested outcome. It provides no indication of which party, if any, held a stronger legal position.
Zanubrutinib is a selective BTK (Bruton’s tyrosine kinase) inhibitor approved under the brand name Brukinsa for B-cell malignancies including mantle cell lymphoma and CLL/SLL. Its commercial value makes it a target for generic ANDA filings, triggering Hatch-Waxman patent litigation. BeiGene has built a multi-patent portfolio around zanubrutinib to protect its market position against generic entry.
PatSnap Eureka searches patents and litigation data to answer instantly.